Osteoprotegerin Inhibits Calcification of Vascular Smooth Muscle Cell via Down Regulation of the Notch1-RBP-Jκ/Msx2 Signaling Pathway

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Zhou, Shaoqiong ^a   Fang, Xing ^a   Xin, Huaping ^a   Li, Wei ^a   Qiu, Hongyu ^b   Guan, Siming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; ALKALINE PHOSPHATASE; CALCIUM; MESSENGER RNA; NOTCH1 RECEPTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR RBP JK; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVITY; MALE; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THORACIC AORTA; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL CALCIFICATION; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; HOMEODOMAIN PROTEINS; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE-BINDING PROTEIN; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOBLASTS; OSTEOPROTEGERIN; RATS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION;

RATTUS;

EID: 84879951237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068987     Document Type: Article

References (51)

1. O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, et al. (2000) American College of Cardiology/American Heart Association Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease: Committee Members. Circulation 102: 126-140. doi:10.1161/01.CIR.102.1.126. PubMed: 10880426.
2. Moe SM, Chen NX, (2004) Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95: 560-567. doi:10.1161/01.RES.0000141775.67189.98. PubMed: 15375022.
3. Shao JS, Cheng SL, Sadhu J, Towler DA, (2010) Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 55: 579-592. doi:10.1161/HYPERTENSIONAHA.109.134205. PubMed: 20101002.
4. RJ R, (2009) Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 5: 185-197.
5. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM, (2006) Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med 260: 192-210. doi:10.1111/j.1365-2796.2006.01692.x. PubMed: 16918817.
6. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, et al. (2007) Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 49: 1860-1870. doi:10.1016/j.jacc.2006.10.079. PubMed: 17481445.
7. Zampetaki A, Zhang ZY, Hu YH, Xu QB, (2005) Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-kappa B signaling pathways. Am J Physiol Heart Circ Physiol 288: H2946-H2954. doi:10.1152/ajpheart.00919.2004. PubMed: 15681696.
8. Mulvihill ER, Jaeger J, Sengupta R, Ruzzo WL, Reimer C, et al. (2004) Atherosclerotic plaque smooth muscle cells have a distinct phenotype. Arterioscler Thromb Vasc Biol 24: 1283-1289. doi:10.1161/01.ATV.0000132401.12275.0c. PubMed: 15142862.
9. Yasuda H, (1998) Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro. Endocrinology 139: 1329-1337. doi:10.1210/en.139.3.1329. PubMed: 9492069.
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, et al. (1998) osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268. doi:10.1101/gad.12.9.1260. PubMed: 9573043.
11. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, et al. (1998) Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin. Biochem Biophys Res Commun 247: 610-615. doi:10.1006/bbrc.1998.8697. PubMed: 9647741.
12. Morrow D, Guha S, Sweeney C, Birney Y, Walshe T, et al. (2008) Notch and Vascular Smooth Muscle Cell Phenotype. Circ Res 103: 1370-1382. doi:10.1161/CIRCRESAHA.108.187534. PubMed: 19059839.
13. Langdon T, Hayward P, Brennan K, Wirtz-Peitz F, Sanders P, et al. (2006) Notch receptor encodes two structurally separable functions in Drosophila: a genetic analysis. Dev Dyn 235: 998-1013. doi:10.1002/dvdy.20735. PubMed: 16534797.
14. Shimizu T, Tanaka T, Iso T, Doi H, Sato H, et al. (2009) Notch Signaling Induces Osteogenic Differentiation and Mineralization of Vascular Smooth Muscle Cells Role of Msx2 Gene Induction via Notch-RBP-Jκ Signaling. Arterioscler Thromb Vasc Biol 29: 1104-U1186. doi:10.1161/ATVBAHA.109.187856. PubMed: 19407244.
15. Orita Y, Yamamoto H, Kohno N, Sugihara M, Honda H, et al. (2007) Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol 27: 2058-2064. doi:10.1161/ATVBAHA.107.147868. PubMed: 17615383.
16. Qiu H, Zhu Y, Sun Z, Trzeciakowski JP, Gansner M, et al. (2010) Short communication: vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with aging. Circ Res 107: 615-619. doi:10.1161/CIRCRESAHA.110.221846. PubMed: 20634486.
17. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, et al. (2006) Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 26: 2117-2124. doi:10.1161/01.ATV.0000236428.91125.e6. PubMed: 16840715.
18. Rasmussen LM, Ledet T, (2005) Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res 37 (Suppl 1):: 90-94. doi:10.1055/s-2005-861371. PubMed: 15918117.
19. Fu M, Zhang J, Lin YgY, Zhu X, Willson TM, et al. (2002) Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun 294: 597-601. doi:10.1016/S0006-291X(02)00533-8. PubMed: 12056809.
20. Zhang J, Fu M, Myles D, Zhu X, Du J, et al. (2002) PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 521: 180-184. doi:10.1016/S0014-5793(02)02872-7. PubMed: 12067713.
21. Venuraju SM, Yerramasu A, Corder R, Lahiri A, (2010) Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 55: 2049-2061. doi:10.1016/j.jacc.2010.03.013. PubMed: 20447527.
22. Olesen P, Ledet T, Rasmussen LM, (2005) Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 48: 561-568. doi:10.1007/s00125-004-1652-8. PubMed: 15700136.
23. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319. doi:10.1016/S0092-8674(00)80209-3. PubMed: 9108485.
24. Collin-Osdoby P, (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95: 1046-1057. doi:10.1161/01.RES.0000149165.99974.12. PubMed: 15564564.
25. Price PA, June HH, Buckley JR, Williamson MK, (2001) Osteoprotegerin Inhibits Artery Calcification Induced by Warfarin and by Vitamin D. Arterioscler Thromb Vasc Biol 21: 1610-1616. doi:10.1161/hq1001.097102. PubMed: 11597934.
26. Mogelvang R, Haahr-Pedersen S, Bjerre M, Frystyk J, Iversen A, et al. (2013) Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 99: 106-110. doi:10.1136/heartjnl-2013-304019.189. PubMed: 23135978.
27. Nybo M, Rasmussen LM, (2008) The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 159: 603-608. doi:10.1530/EJE-08-0554. PubMed: 18697793.
28. Augoulea A, Vrachnis N, Lambrinoudaki I, Dafopoulos K, Iliodromiti Z, et al. (2013) Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol, 2013(2013): 182060. PubMed: 23401681.
29. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, et al. (2008) Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51: 627-633. doi:10.1016/j.jacc.2007.09.058. PubMed: 18261681.
30. Jono S, Ikari Y, Shioi A, Mori K, Miki T, et al. (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106: 1192-1194. doi:10.1161/01.CIR.0000031524.49139.29. PubMed: 12208791.
31. Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, et al. (2005) Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 109: 389-395. doi:10.1042/CS20050058. PubMed: 15926884.
32. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, et al. (2006) Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26: 857-863. doi:10.1161/01.ATV.0000204334.48195.6a. PubMed: 16424351.
33. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, et al. (2010) Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 30: 1849-1854. doi:10.1161/ATVBAHA.109.199661. PubMed: 20448212.
34. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, et al. (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109: 2175-2180. doi:10.1161/01.CIR.0000127957.43874.BB. PubMed: 15117849.
35. Browner WS, Lui LY, Cummings SR, (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86: 631-637. doi:10.1210/jc.86.2.631. PubMed: 11158021.
36. Wasilewska A, Rybi-Szuminska A, Zoch-Zwierz W, (2010) Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. Pediatr Nephrol 25: 2067-2075. doi:10.1007/s00467-010-1583-1. PubMed: 20602239.
37. Baber U, de Lemos JA, Khera A, McGuire DK, Omland T, et al. (2008) Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int 73: 615-621. doi:10.1038/sj.ki.5002716. PubMed: 18075501.
38. Albalate M, de la Piedra C, Fernández C, Lefort M, Santana H, et al. (2006) Association between phosphate removal and markers of bone turnover in haemodialysis patients. Nephrol Dial Transplant 21: 1626-1632. doi:10.1093/ndt/gfl034. PubMed: 16490746.
39. Mazzaferro S, Pasquali M, Pugliese F, Barresi G, Carbone I, et al. (2007) Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis. Am J Nephrol 27: 75-83. doi:10.1159/000099095. PubMed: 17259697.
40. Sigrist MK, Levin A, Er L, McIntyre CW, (2009) Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 24: 3157-3162. doi:10.1093/ndt/gfp253. PubMed: 19491380.
41. Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, et al. (2001) Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 38: S175-S177. doi:10.1053/ajkd.2001.27437. PubMed: 11576949.
42. Fahrleitner A, Prenner G, Leb G, Tscheliessnigg KH, Piswanger-Sölkner C, et al. (2003) Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 32: 96-106. doi:10.1016/S8756-3282(02)00926-2. PubMed: 12584041.
43. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, et al. (2008) NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem 283: 6509-6518. doi:10.1074/jbc.M707000200. PubMed: 18156632.
44. Acharya A, Hans CP, Koenig SN, Nichols HA, Galindo CL, et al. (2011) Inhibitory role of Notch1 in calcific aortic valve disease. PLOS ONE 6: e27743. doi:10.1371/journal.pone.0027743. PubMed: 22110751.
45. Niessen K, Karsan A, (2008) Notch signaling in cardiac development. Circ Res 102: 1169-1181. doi:10.1161/CIRCRESAHA.108.174318. PubMed: 18497317.
46. Nigam V, Srivastava D, (2009) Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 47: 828-834. doi:10.1016/j.yjmcc.2009.08.008. PubMed: 19695258.
47. Lee HL, Woo KM, Ryoo HM, Baek JH, (2010) Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 391: 1087-1092. doi:10.1016/j.bbrc.2009.12.027. PubMed: 20004646.
48. Shimizu T, Tanaka T, Iso T, Kurabayashi M, (2008) Notch Signaling Directly Targets Msx2: Possible Role of Notch Signaling in Osteogenic Conversion of Vascular Smooth Muscle Cells and Vascular Calcification. Circulation 118: S368-S368.
49. Nie B, Zhou S, Fang X, Li W, Wang B, et al. (2012) Implication of receptor activator of NF-kappaB ligand in Wnt/beta-catenin pathway promoting osteoblast-like cell differentiation. J Huazhong Univ Sci Technol Med Sci 32: 818-822. doi:10.1007/s11596-012-1040-4. PubMed: 23271279.
50. Xin H, Xin F, Zhou S, Guan S, (2013) The Wnt5a/Ror2 pathway is associated with determination of the differentiation fate of bone marrow mesenchymal stem cells in vascular calcification. Int J Mol Med 31: 583-588. PubMed: 23337931.
51. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, et al. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97: 887-892. doi:10.1002/cncr.11138. PubMed: 12548591.